
|Videos|August 25, 2015
What Does the Future Hold for Biosimilars in the United States?
Author(s)Davy James, Managing Editor
Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.
Advertisement
Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Clinical Manifestations and Prognostic Impact of Anemia in Myelofibrosis
2
Trump Announces Pricing Deals With 9 Drugmakers, Expanding Most-Favored-Nation Drug Pricing Strategy
3
More Dose Adjustments, Similar Outcomes: Ribociclib vs Palbociclib in Practice
4
Understanding Myelofibrosis and the Central Role of JAK Pathway Dysregulation
5




































































































































































































